Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Net Cash Flow (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Net Cash Flow for 6 consecutive years, with -$17.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 137.52% to -$17.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$26.3 million, a 157.98% decrease, with the full-year FY2025 number at -$26.3 million, down 157.98% from a year prior.
  • Net Cash Flow was -$17.1 million for Q4 2025 at TScan Therapeutics, down from $112000.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $101.6 million in Q2 2024 to a low of -$109.0 million in Q3 2024.
  • A 5-year average of -$681250.0 and a median of -$15.9 million in 2021 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: soared 1167.38% in 2021, then tumbled 558.42% in 2023.
  • TScan Therapeutics' Net Cash Flow stood at -$16.5 million in 2021, then dropped by 4.91% to -$17.3 million in 2022, then decreased by 26.36% to -$21.8 million in 2023, then soared by 308.72% to $45.6 million in 2024, then plummeted by 137.52% to -$17.1 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Net Cash Flow are -$17.1 million (Q4 2025), $112000.0 (Q3 2025), and $15.3 million (Q2 2025).